Tower Research Capital LLC (Trc) Instil Bio, Inc. Transaction History

Tower Research Capital LLC (Trc)

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$0.4 - $0.63 $6,090 - $9,593	-15,227 Reduced 36.89%	26,055 $11,000
Q2 2023 Aug 14, 2023	BUY	$0.51 - $0.67 $6,353 - $8,346	12,458 Added 43.22%	41,282 $22,000
Q1 2023 May 09, 2023	BUY	$0.6 - $0.91 $5,953 - $9,029	9,923 Added 52.5%	28,824 $19,000
Q4 2022 Feb 10, 2023	BUY	$0.48 - $5.33 $6,736 - $74,806	14,035 Added 288.43%	18,901 $12,000
Q3 2022 Nov 10, 2022	SELL	$4.65 - $7.37 $11,722 - $18,579	-2,521 Reduced 34.13%	4,866 $24,000
Q2 2022 Aug 15, 2022	BUY	$4.21 - $11.15 $26,392 - $69,899	6,269 Added 560.73%	7,387 $34,000
Q1 2022 May 12, 2022	BUY	$8.48 - $18.1 $661 - $1,411	78 Added 7.5%	1,118 $12,000
Q4 2021 Feb 14, 2022	SELL	$15.37 - $22.5 $11,512 - $16,852	-749 Reduced 41.87%	1,040 $18,000
Q3 2021 Nov 15, 2021	BUY	$15.05 - $23.28 $22,033 - $34,081	1,464 Added 450.46%	1,789 $32,000
Q2 2021 Aug 16, 2021	SELL	$15.31 - $24.63 $45,072 - $72,510	-2,944 Reduced 90.06%	325 $6,000
Q1 2021 May 17, 2021	BUY	$24.23 - $27.06 $79,207 - $88,459	3,269 New	3,269 $82,000

1.9M

Ticker TIL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,694,000
Market Cap $2.84B
Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of patients with cancer. The company develops cell therapy of autologous tumor infiltrating lymphocyte (TIL). Its TIL product candidates in pipeline include ITIL-168 for indications, such as melanoma, cutaneous squamous cell carcinoma, non-small ce...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.